Roche makes access to its PCR patent portfolio readily available worldwide through licensing programs. Roche offers companies rights to make PCR products for human or veterinary diagnostic testing, and also licenses labs to perform PCR-based human or veterinary diagnostic testing.
Roche’s out-licensing programs encompass not only the field of diagnostics but that of diagnostics research as well, which applies to activities related to research, development and improvement of products and processes for the human diagnostics field.
Our in-licensing efforts focus on supporting the development of innovative and novel molecular diagnostics tests.
Today, polymerase chain reaction (PCR) makes its presence felt in a wide array of applications, from forensic science and matching organ donors to identifying endangered species.
From reverse transcription to real-time PCR, Roche is behind many of the key advancements in the field of polymerase chain reaction technology.
Polymerase chain reaction (PCR) has revolutionized the field of molecular diagnostics since its conception in 1983. Roche has played a pioneering role from the start.
Polymerase chain reaction (PCR) is an efficient and cost-effective way to copy or “amplify” small segments of DNA or RNA.